AbbVie Submits BLA for Etentamig to FDA for Relapsed/Refractory Multiple Myeloma

A BCMA-directed bispecific antibody with community-care dosing ambitions is now under FDA review: AbbVie has submitted a Biologics License Application for etentamig, a second-generation BCMA x CD3 T-cell engager administered intravenously, targeting adults with relapsed or refractory multiple myeloma. For regulatory affairs and CMC teams, the submission opens a PDUFA clock and signals near-term scrutiny of manufacturing controls, cold-chain logistics, and the step-up dosing protocols that define this antibody class.

The BLA is anchored by the global, Phase 3, multicenter, randomized CERVINO study, which evaluated etentamig against investigator's choice of standard available therapies in triple-class exposed patients who had received at least two prior lines of therapy. Etentamig met both dual primary endpoints: an overall response rate of 74.0% versus 45.7% for standard therapy, and a 60% reduction in progression-free survival risk. Discontinuations due to treatment-emergent adverse events were notably lower in the etentamig arm at 3.6%, compared with 14% for standard therapy.

The safety profile carries direct implications for site qualification and monitoring infrastructure. Among patients receiving a single step-up dose, cytokine release syndrome incidence was 28.3%, with all events grading at 1 or 2 and no grade 3 or higher events reported. One grade 1 ICANS event was observed. Grade 3/4 infections occurred in 27.7% of etentamig patients versus 19.2% in the comparator arm, though grade 5 infections were less frequent with etentamig at 1.5% versus 3.1%. QA and pharmacovigilance leads should map these event profiles against existing risk management frameworks for bispecific antibody programs.

AbbVie's stated intent to support treatment delivery in community-based settings introduces a distinct manufacturing and distribution consideration. Monthly dosing from initiation, if reflected in labeling, would require supply chain planning calibrated to outpatient infusion volumes rather than specialized academic center throughput. CMC submissions for IV-administered biologics of this class typically face close agency review of formulation stability, container closure integrity, and in-use hold times relevant to community infusion environments.

The CERVINO data, read against the existing competitive landscape of approved BCMA-directed agents, positions etentamig as a potential entrant into a class where differentiation increasingly turns on tolerability and administration flexibility rather than mechanism alone.

The PDUFA date, once assigned, will set the operational timeline for manufacturing readiness, label negotiations, and distribution network activation across the sites AbbVie intends to serve at launch.

Source: AbbVie News Center via PR Newswire, October 27, 2026.